In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Related to this article
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Advertisement
Advertisement
Trending on Urology Times
1
Closing Risk Stratification Gaps in Localized Prostate Cancer With AI
2
FDA updates in urology: September 2026
3
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
4
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
5